FDA declines approval of ticagrelor without additional information
The FDA has issued a complete response letter to AstraZeneca that requests additional analyses of the PLATO data in response to the company’s New Drug Application for its P2Y12 inhibitor, ticagrelor. This comes after the Cardiovascular and Renal Drugs Advisory Committee voted 7-1 in July to recommend approval of the drug for the reduction of thrombotic events in patients with acute coronary syndromes.
According to a press release issued by AstraZeneca, the FDA requested only additional analyses of the data presented in the PLATO trial and did not request that additional studies be conducted as a prerequisite for approval. AstraZeneca will be evaluating the contents of the letter and will respond to the agency’s request for additional analyses of the PLATO data as soon as possible, the release stated.
“Our highest priority is to provide the requested PLATO analyses to the FDA and progress to completion of the Brilinta [ticagrelor] New Drug Approval review,” Martin Mackay, president of research and development at AstraZeneca, said in the release.
Click the links to read Cardiology Today’s coverage of the Cardiovascular and Renal Drugs Advisory Committee vote and of the PLATO trial.
__________________________________________________ ______________________
Cryoballoon catheter approved for treatment of paroxysmal AF
Medtronic’s Arctic Front Cardiac CryoAblation Catheter System has been approved by the FDA for use in the setting of paroxysmal atrial fibrillation, making it the first and only cryoballoon indicated for use in this setting, according to a press release.
The FDA’s approval for the catheter came as a result of the Sustained Treatment of Paroxysmal Atrial Fibrillation (STOP AF) trial, which demonstrated efficacy of the device in the treatment of paroxysmal AF. The cryoballoon has currently been used in more than 10,000 patients in more than 200 centers outside of the United States and will now be available for physicians and patients in this country, the release said.
|